CoreCap Advisors’s Neurocrine Biosciences NBIX Stock Holding History

CoreCap Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$80.1K	Buy	565 +501	+783%	+$80.5K	﹤0.01%	1192
2026 Q2	$10.8K	Buy	64 +48	+300%	+$7.12K	﹤0.01%	2039
2026 Q1	$2.11K	Hold	16	–	–	﹤0.01%	2402
2025 Q4	$2.27K	Buy	+16	New	+$2.32K	﹤0.01%	2447
2024 Q3	–	Sell	-1,022	Closed	-$141K	–	2704
2024 Q2	$141K	Buy	+1,022	New	+$140K	0.01%	431
2022 Q4	$132K	Buy	+1,101	New	+$129K	0.01%	636

Other funds holding NBIX

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

CoreCap Advisors's NBIX Position: Q3 2026 in Review

CoreCap Advisors increased its Neurocrine Biosciences (NBIX) stake by 783% in Q3 2026, buying an estimated $80.5K and bringing the position to 565 shares worth $80.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1192.

CoreCap Advisors first reported a position in NBIX in Q4 2022 and has held it in 6 quarters since. The position peaked at $141K in Q2 2024. 143 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

CoreCap Advisors held 565 shares of Neurocrine Biosciences worth $80.1K as of Q3 2026.
CoreCap Advisors bought 501 Neurocrine Biosciences shares in Q3 2026, an estimated $80.5K.
Neurocrine Biosciences made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1192 holding.
CoreCap Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 6 quarters since.
CoreCap Advisors's Neurocrine Biosciences position peaked at $141K in Q2 2024.
143 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.